Condition: Non-small Cell Lung Cancer · Sponsor: University of Rochester
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.
This description comes directly from the study's public registry record.
Megan Baumgart · 585-275-4401 · Megan_Baumgart@URMC.Rochester.edu
Always discuss trial participation with your own doctor first.
| University of Rochester | Rochester, New York, United States | Not Yet Recruiting |
| University of Rochester | Rochester, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04297605